NEW YORK (GenomeWeb News) – A US Food and Drug Administration panel is tentatively set to meet in four months to discuss Epigenomics’ colorectal cancer screening test, the company said today.
Registering provides access to this and other free content.
Already have an account?Login Now.
A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.
NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.
In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.
Hong Kong is using DNA phenotyping to shame litterers.